GA
VRTX icon

Geller Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Geller Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$236K Sell
586
-1,434
-71% -$665K 0.02% 232
2024
Q3 		$939K Sell
2,020
-754
-27% -$362K 0.07% 79
2024
Q2 		$1.3M Sell
2,774
-38
-1% -$16.5K 0.1% 58
2024
Q1 		$1.18M Sell
2,812
-17
-0.6% -$7.19K 0.1% 64
2023
Q4 		$1.15M Buy
2,829
+109
+4% +$40.3K 0.11% 56
2023
Q3 		$946K Sell
2,720
-105
-4% -$36.7K 0.11% 62
2023
Q2 		$994K Buy
2,825
+921
+48% +$310K 0.12% 54
2023
Q1 		$600K Sell
1,904
-13
-0.7% -$3.9K 0.09% 53
2022
Q4 		$554K Buy
1,917
+75
+4% +$22.9K 0.09% 49
2022
Q3 		$533K Sell
1,842
-56
-3% -$16.1K 0.12% 43
2022
Q2 		$535K Buy
+1,898
New +$508K 0.11% 48

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geller Advisors's VRTX Position: Q4 2024 in Review

Geller Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 71% in Q4 2024, selling an estimated $665K and leaving 586 shares worth $236K. The position accounts for 0.02% of the portfolio, ranked #232.

Geller Advisors first reported a position in VRTX in Q2 2022 and has held it in 11 quarters since. The position peaked at $1.3M in Q2 2024. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Geller Advisors held 586 shares of Vertex Pharmaceuticals worth $236K as of Q4 2024.
  • Geller Advisors sold 1,434 Vertex Pharmaceuticals shares in Q4 2024, an estimated $665K.
  • Vertex Pharmaceuticals made up 0.02% of Geller Advisors's portfolio in Q4 2024, its #232 holding.
  • Geller Advisors first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 11 quarters since.
  • Geller Advisors's Vertex Pharmaceuticals position peaked at $1.3M in Q2 2024.
  • 1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Geller Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.